Tazeen Ahmad
BofA Securities, Research Division

[Audio Gap] here at the Bank of America Healthcare Conference. We're kicking off our very first session of the very first day. It's my pleasure to have with me Scholar Rock as our first presenting company, sitting up here on stage with me is David Hallal, who is, of course, Chief Executive Officer and Chairman. David, good morning. Thanks for making the trip over from the East Coast.

So maybe let's just do a quick overview of the company. Just give us a little bit of an overview of the focus of what you're trying to do and how you might be differentiated from other companies trying to do at least similar indications?

David Hallal
CEO & Chairman of the Board

Thanks, Tazeen. Yes, we're super proud at Scholar Rock to have succeeded where 20, 30 years of failure preceded us. And that is that in 1987 when myostatin was discovered, it was certainly something that just about every biotech or pharma company mostly the big pharma companies have tried to target and block because what myostatin is, of course, is the body's natural negative regulator of growing muscles. So the thought was if one could safely and effectively inhibit myostatin, one could then release muscle growth in the body that could be applied to a set of diseases and certainly, we're focused on rare neuromuscular.

So we had an idea when we started the company at Scholar Rock, which was if we could do it slightly differently, we may be able to really harness